Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) stands out as a compelling pick for investors following Louis Navellier’s growth-focused strategy. The biopharmaceutical company, which specializes in autoimmune disease treatments, meets multiple criteria outlined in Navellier’s "The Little Book That Makes You Rich." Below, we examine why AUPH fits this approach.

Key Strengths Aligning with Navellier’s Growth Criteria

• Earnings Revisions & Surprises: Analysts have raised next-quarter EPS estimates by 33.3% over the past three months. AUPH has also exceeded earnings expectations in each of the last four quarters, with an average surprise of 197.4%.
• Sales & Earnings Growth: Revenue grew 29.2% year-over-year, while quarterly sales increased 24.2%. EPS surged 171.8% over the past year and 633.3% quarter-over-quarter.
• Operating Margin Expansion: Operating margins improved by 154.5% year-over-year, reflecting stronger profitability.
• Cash Flow Strength: Free cash flow jumped 198.2% in the past year, indicating financial flexibility.
• High Return on Equity: An ROE of 11.4% demonstrates efficient use of shareholder capital.

Fundamental Health

AUPH’s financial health is solid, with strong liquidity (current ratio of 5.93) and manageable debt levels. While past profitability has been inconsistent, recent margins and returns rank near the top of the biotechnology industry. Valuation metrics suggest the stock remains reasonably priced relative to peers, with a forward P/E of 11.89.

For a deeper analysis, review the full fundamental report on AUPH.

Our Little Book Growth Stock Screener provides more stocks matching this strategy.

Disclaimer

This is not investing advice. Always conduct your own research before making investment decisions.